Epic Research is not viewable using Internet Explorer. Please try accessing it with an alternate browser.
Displaying 201-220 of 324 Articles

All Articles

Median Weight Loss for Diabetic & Non-Diabetic Patients on 2.4 mg SemaglutideExpand
April 25, 2023

Weight Change With Semaglutide

Semaglutide injections, also known as Ozempic and Wegovy, lead to weight loss in both diabetics and non-diabetics. This study is an observational analysis of the data and not a recommendation for use of semaglutide as a treatment, since the side effects must be considered.

Impact of COVID-19 In Utero Exposure on Developmental or Congenital Disorders in InfantsExpand
March 15, 2023

Development of Infants Born to COVID-Positive Mothers 

Babies born to women who test positive for COVID-19 during pregnancy showed slightly elevated rates of congenital cardiovascular defects, heart rhythm abnormalities, metabolic disorders, and perinatal respiratory disorders during the infant’s first year of life.

Percentage of Encounters for Flu or Stroke DiagnosesExpand
March 7, 2023

No ‘Season’ for Strokes 

Despite studies suggesting an increased risk of stroke after influenza infection, we do not see this trend on a population level.

Fentanyl Testing in the EDExpand
August 23, 2022

Only 5% of Overdose Patients Tested for Fentanyl, #1 Killer of Americans 18-45

While standard toxicology screenings test for opiates, chemicals extracted from natural sources such as morphine (an indicator of heroin use), most of these screenings do not detect fentanyl, a synthetic opioid. Patients who are treated in the emergency department for overdoses are tested for fentanyl in only 5% of cases, and fentanyl is detected in almost 50% of these tests. As overdose deaths from synthetic opioids were 18 times more likely in 2020 than in 2013, updating screening protocols to include fentanyl testing would be prudent.